HOME >> BIOLOGY >> NEWS
Combination drug therapy drastically reduces multiple coronary heart disease risk factors

DALLAS April 12, 2003 Combining two lipid-lowering medications safely and effectively reduces multiple coronary heart disease risk factors, according to UT Southwestern Medical Center at Dallas researchers.

The researchers combined a low dose of a medication that targets low-density lipoprotein (LDL) cholesterol, or the bad cholesterol, with a second drug therapy that increases high-density lipoprotein (HDL), the good cholesterol. The study involved 20 patients with combined hyperlipidemia, which is primarily characterized by high triglycerides, high LDL cholesterol and low HDL cholesterol.

The study, reported in the April 15 issue of the American Journal of Cardiology, found that a specific drug combination low-dose simvastatin (Zocor) and fenofibrate resulted in a 52 percent reduction in triglycerides, a 23 percent increase in HDL and a 28 percent reduction in LDL.

Drug treatment for combined hyperlipidemia presents a challenge because single drug therapy rarely corrects all of the lipoprotein abnormalities observed in this condition, said Dr. Gloria Vega, professor of clinical nutrition and the studys principal investigator. High LDL is a well-established risk factor for coronary heart disease, and high triglycerides and low HDL worsen the risk. Successful management of this condition may require combined drug therapy.

This study provides reasonable evidence that a low dose of a statin plus fenofibrate is a relatively safe and effective drug combination for treating LDL and several emerging risk factors for coronary heart disease. No significant side effects were observed with either the cholesterol-lowering drug alone or with co-administration of the statin and fenofibrate, said Vega.

Dr. Nilo Cater, assistant professor of internal medicine and co-author of the study, said, The rationale for looking into the combination is that there are not only people who have elevations in their LDL, but they also have abnormalities
'"/>

Contact: Amy Shields
amy.shields@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
11-Apr-2003


Page: 1 2

Related biology news :

1. Combination of gene therapy and gene silencing prevents neurodegenerative disease
2. Combination therapy dramatically improves function after spinal cord injury in rats
3. Combination therapy drives cancer into remission
4. Combination therapy improves anthrax survival
5. Drug Combination May Prove Effective To Prevent Recurrence Of Hepatitis C After Transplantation
6. Combination Therapy For Brain Tumors Holds Promise For Longer Survival After Surgery
7. New Heart-Attack Indicator Dramatically Improves Diagnostic Accuracy Of ER Doctors: TnT/Echocardiogram Combination Could Reduce Needless Admissions
8. Dangerous Chemical Combination Presents Possible Scenario For Gulf War Illnesses
9. Targeted therapy knocks out pediatric brain cancer in mice
10. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
11. Columbia research to examine gene influence on severity of peridontal disease, therapy response

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... ... 19, 2020 , ... “How can we help?”, asks Hans ... Bioscience for more than twenty years. Together with Douglas Granger, Ph.D., founder of ... Foundations of Interdisciplinary Saliva Research and Applications ," and Steven Granger, Ph.D., Chief ...
(Date:8/21/2020)... ... August 20, 2020 , ... ... Movahhed , a Clinical Operations executive with expertise in clinical trial planning and ... firm as an Expert Consultant. Throughout his career, Mr. Movahhed has helped design ...
(Date:8/12/2020)... ... August 12, 2020 , ... Mosio recently ... ideal for public health agencies of all sizes. With a focus on tracking ... individuals find appropriate health care, Mosio helps public health departments automate communications and ...
Breaking Biology News(10 mins):
(Date:8/31/2020)... ... August 29, 2020 , ... DuPont ... capability in Wuxi, China. The new plant operation will provide the local animal ... technology. , “This facility will improve the flexibility of our offerings to ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... cold chain validation engineering firm, is making available for free its new ... to incorporate concurrent transport simulation testing into today’s biologics licensing application (BLA). ...
(Date:8/3/2020)... , ... August 03, 2020 , ... Introducing Ardent Animal ... transformative growth, , Known as MediVet Biologics since its formation ... The new Ardent Animal Health will build on its base of innovative ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... combine up to three different materials for use with CRM, neurostimulation, vascular, and ... three materials to meet specific design requirements, performance, and cost criteria; especially where ...
Breaking Biology Technology:
Cached News: